<DOC>
	<DOCNO>NCT01209650</DOCNO>
	<brief_summary>The program provide early access investigational drug BIBW 2992 treat patient advance NSCLC fail least 12 week erlotinib gefitinib . The Compassionate Use Programme also provide additional safety efficacy information BIBW 2992 use . Named Patient Use ( NPU )</brief_summary>
	<brief_title>LUX Lung Special Access Scheme Australia Named Patient Use ( NPU )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Patients pathologic confirmation adenocarcinoma lung Stage IIIB pleural effusion Stage IV Exclusion criterion : Brain metastases symptomatic ; patient treat , asymptomatic brain metastasis eligible stable brain disease least four 4 week without requirement steroid anti epileptic therapy Significant recent acute gastrointestinal disorder diarrhea major symptom judge investigator . Patients lifethreatening illness organ system dysfunction , opinion investigator , would either compromise patient safety interfere evaluation safety test drug History cardiac disease clinically significant , judged investigator uncontrolled cardiac disease ( include congestive heart failure , angina , myocardial infarction , arrhythmia , include New York Heart Association ( NYHA ) functional classification 3 ) Cardiac leave ventricular function rest ejection fraction le 50 % Bilirubin 1.5 mg / dl ( 26 mol / L , SI unit equivalent ) Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) three time upper limit normal ( related liver metastases five time upper limit normal ) Serum creatinine 1.5 time upper normal limit calculated/measured creatine clearance 45ml/min Women childbearing potential men able father child unwilling use medically acceptable method contraception trial Pregnancy breast feeding Patients unable comply protocol Patients know HIV , active hepatitis B active hepatitis C Preexisting Interstitial Lung Disease ( ILD ) Requirement treatment prohibit concomitant medication list Section 4.2.2.1 . Patients already pretreated BIBW 2992</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>